EGFR mutations, a prevalent oncogenic driver in lung adenocarcinomas among the Caucasian population, occur in approximately 11–15% of cases and represent the most common targetable oncogenic addiction in the first-line setting [3]. This evidence concerns the gene EGFR and lung adenocarcinoma.